Cargando…
Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
BACKGROUND: We designed this randomised, open-label, parallel group, multi-centre study to investigate the efficacy and safety of glycopyrronium/formoterol, a long-acting muscarinic antagonist/long-acting β2-agonist fixed dose combination, delivered through a dry powder inhaler (DPI) in patients wit...
Autores principales: | Salvi, Sundeep, Kumar, Anand, Agrawal, Sumit, Leuva, Amritlal, Shukla, Vineet Kumar, Deshpande, Shrikant Vishnu, Balamurugan, Santhalingam, Singh, Ajit, Tikkiwal, Sharad, Gupta, Sandeep K., Singh, Bhanu Pratap, Lopez, Meena, Sawant, Sandesh, Vaidya, Abhijit, Gogtay, Jaideep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623852/ https://www.ncbi.nlm.nih.gov/pubmed/36629200 http://dx.doi.org/10.4103/lungindia.lungindia_92_22 |
Ejemplares similares
-
A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation
por: Salvi, Sundeep S, et al.
Publicado: (2016) -
Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
por: Salvi, Sundeep, et al.
Publicado: (2022) -
Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021) -
Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021) -
Author's reply
por: Salvi, Sundeep Santosh, et al.
Publicado: (2017)